Genomic Health (GHDX) Q4 Revenue Tops Views, Offers Guidance

Genomic Health (NASDAQ: GHDX) reported Q4 EPS of $0.23, may not compare to the analyst estimate of $0.30. Revenue for the quarter came in at $104.6 million versus the consensus estimate of $101.51 million.

GUIDANCE:

Genomic Health sees FY2019 EPS of $1.38-$1.54, versus the consensus of $1.25. Genomic Health sees FY2019 revenue of $436-448 million, versus the consensus of $438.82 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c